Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US
Abstract Introduction Limited information exists on the epidemiology, treatment, and burden of palmoplantar pustulosis (PPP) and defining the optimal course of treatment remains challenging without approved targeted treatments in most countries. Here, we describe the clinical and demographic charact...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-03-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-024-01109-z |
| _version_ | 1797233730074443776 |
|---|---|
| author | Alvan Cheng Xinqing Deng Fang Yang Cici Liu David Neasham Thomas Kilcoyne Michael Duxbury Myriam Cordey Boni E. Elewski |
| author_facet | Alvan Cheng Xinqing Deng Fang Yang Cici Liu David Neasham Thomas Kilcoyne Michael Duxbury Myriam Cordey Boni E. Elewski |
| author_sort | Alvan Cheng |
| collection | DOAJ |
| description | Abstract Introduction Limited information exists on the epidemiology, treatment, and burden of palmoplantar pustulosis (PPP) and defining the optimal course of treatment remains challenging without approved targeted treatments in most countries. Here, we describe the clinical and demographic characteristics, treatments received, and negative health outcomes experienced among patients with PPP in the United States (US) and Germany. Methods Retrospective cohort study between 2016 and 2021 using data from the US Merative™ MarketScan® Research Database and IQVIA™ German Disease Analyzer. Adult patients with PPP (ICD-10-CM L40.3) were followed from the date of their first qualifying PPP diagnosis and continued until the earlier of disenrollment or end date of database, during which treatment patterns and incidence rates of negative health outcomes were assessed. Treatment patterns included adherence, non-persistence, discontinuation, re-initiation, switching, and combination therapy. Results The prevalence of PPP was 0.005% and 0.065% in the MarketScan database and German Disease Analyzer, respectively, with 1629 and 3866 patients meeting the inclusion criteria. Most patients were female (71.3%, 67.8%), with mean (SD) age of 54.1 (11.7) and 56.9 (14.3) years, respectively. One year post index, most patients received topical treatment (77.4%, 65.3%), but non-persistence and discontinuation were high. Oral and biologic treatments displayed higher levels of adherence, particularly apremilast and tofacitinib among oral treatments and TNF inhibitors and IL-23 inhibitors among biologics. Rates of negative health outcomes were higher among patients not receiving treatment post-index compared with those receiving treatment post-index across both databases, regardless of prior treatment history. Conclusions Establishing treatment guidelines remains an unmet need for patients with PPP and could improve quality of life by reducing the occurrence of negative health outcomes. The findings from this study may provide insight into the effectiveness of current treatment options for patients with PPP and can be leveraged to support the development of treatment guidelines. |
| first_indexed | 2024-04-24T16:20:48Z |
| format | Article |
| id | doaj.art-364b21bb84124bd790b5b101e2731595 |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-04-24T16:20:48Z |
| publishDate | 2024-03-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-364b21bb84124bd790b5b101e27315952024-03-31T11:11:12ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722024-03-0114362764110.1007/s13555-024-01109-zTreatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the USAlvan Cheng0Xinqing Deng1Fang Yang2Cici Liu3David Neasham4Thomas Kilcoyne5Michael Duxbury6Myriam Cordey7Boni E. Elewski8Center for Observational Research, Amgen, Inc.SimulStat Inc.SimulStat Inc.SimulStat Inc.Center for Observational Research, Amgen, LtdHobson PriorKelly Services, Inc.Center for Observational Research, Amgen, Inc.Department of Dermatology, University of Alabama at BirminghamAbstract Introduction Limited information exists on the epidemiology, treatment, and burden of palmoplantar pustulosis (PPP) and defining the optimal course of treatment remains challenging without approved targeted treatments in most countries. Here, we describe the clinical and demographic characteristics, treatments received, and negative health outcomes experienced among patients with PPP in the United States (US) and Germany. Methods Retrospective cohort study between 2016 and 2021 using data from the US Merative™ MarketScan® Research Database and IQVIA™ German Disease Analyzer. Adult patients with PPP (ICD-10-CM L40.3) were followed from the date of their first qualifying PPP diagnosis and continued until the earlier of disenrollment or end date of database, during which treatment patterns and incidence rates of negative health outcomes were assessed. Treatment patterns included adherence, non-persistence, discontinuation, re-initiation, switching, and combination therapy. Results The prevalence of PPP was 0.005% and 0.065% in the MarketScan database and German Disease Analyzer, respectively, with 1629 and 3866 patients meeting the inclusion criteria. Most patients were female (71.3%, 67.8%), with mean (SD) age of 54.1 (11.7) and 56.9 (14.3) years, respectively. One year post index, most patients received topical treatment (77.4%, 65.3%), but non-persistence and discontinuation were high. Oral and biologic treatments displayed higher levels of adherence, particularly apremilast and tofacitinib among oral treatments and TNF inhibitors and IL-23 inhibitors among biologics. Rates of negative health outcomes were higher among patients not receiving treatment post-index compared with those receiving treatment post-index across both databases, regardless of prior treatment history. Conclusions Establishing treatment guidelines remains an unmet need for patients with PPP and could improve quality of life by reducing the occurrence of negative health outcomes. The findings from this study may provide insight into the effectiveness of current treatment options for patients with PPP and can be leveraged to support the development of treatment guidelines.https://doi.org/10.1007/s13555-024-01109-zPalmoplantar pustulosisPsoriasisBurdenHealthcare utilizationTreatment patternsOutcomes |
| spellingShingle | Alvan Cheng Xinqing Deng Fang Yang Cici Liu David Neasham Thomas Kilcoyne Michael Duxbury Myriam Cordey Boni E. Elewski Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US Dermatology and Therapy Palmoplantar pustulosis Psoriasis Burden Healthcare utilization Treatment patterns Outcomes |
| title | Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US |
| title_full | Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US |
| title_fullStr | Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US |
| title_full_unstemmed | Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US |
| title_short | Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US |
| title_sort | treatment patterns and negative health outcomes in palmoplantar pustulosis patients in germany and the us |
| topic | Palmoplantar pustulosis Psoriasis Burden Healthcare utilization Treatment patterns Outcomes |
| url | https://doi.org/10.1007/s13555-024-01109-z |
| work_keys_str_mv | AT alvancheng treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT xinqingdeng treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT fangyang treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT ciciliu treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT davidneasham treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT thomaskilcoyne treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT michaelduxbury treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT myriamcordey treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus AT bonieelewski treatmentpatternsandnegativehealthoutcomesinpalmoplantarpustulosispatientsingermanyandtheus |